Suven Life Sciences is participating and presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s Disease at 11th clinical trials on Alzheimer's disease (CTAD) during October 24-27, 2018 at Barcelona, Spain.
SUVN-502 is a promising pure, 5-HT6 receptor antagonist in development for the treatment of moderate Alzheimer’s disease, a novel triple combination treatment approach. This trial evaluates the efficacy and safety of SUVN-502 added to background stable donepezil and memantine, a triple therapy in subjects with moderate AD dementia.
At CTAD, Suven is presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s disease. Top-line efficacy results from this study are expected during August/September of 2019
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
